Pædiatrisk onkologi på Rigshospitalet
Læs en beskrivelse af specialet 'pædiatrisk onkologi' på Rigshospitalet
Understanding Gastrointestinal Intolerance induced by low-dose Methotrexate in Childhood Leukaemia and Juvenile Idiopathic Arthritis
Juvenile Idiopathic Arthritis (JIA) is the most common chronic paediatric rheumatic disease. Without treatment the disease causes significant short- and long-term disability and quality of life impairment. Prognosis has greatly improved within recent years as a result of substantial progress in disease management and low-dose methotrexate (MTX) is a mainstay in the treatment of JIA. Childhood leukaemia (Acute Lymphoblastic Leukaemia, ALL) is the most frequent malignancy in the paediatric population. Survival rates have reached above 85% due to advances in chemotherapy. MTX is also a mainstay in the treatment of ALL.
Gastrointestinal toxicity is a well-known challenge associated to high-dose MTX treatment of ALL. However this is not described as a significant problem among these children when they reach maintenance treatment and receive low-dose MTX treatment. Children with JIA also receive low-dose MTX treatment. Among these patients MTX induced gastrointestinal intolerance is a significant problem.
Studies have shown that more than half of the JIA patients have problems tolerating MTX because of nausea, which may lead to cessation of treatment. It is largely unknown why MTX causes nausea but both pharmacogenetic and psychological factors are thought to play a role.
The aim of this project is to create a greater understanding of gastrointestinal intolerance associated to low-dose methotrexate treatment by investigating the differences between these two patient groups, investigating genetic and psychological factors.
Tilknyttet Karsten Nysoms gruppe.
Marie Louise Sjødin Nillson står for daglige gennemførelse af projektet.